Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

28. Juni 2016 07:30 ET | Quelle: Marinus Pharmaceuticals, Inc.

Results from Phase 2 Exploratory Clinical Study Support Continued Development of Ganaxolone in Fragile X Syndrome

Anxiety and Hyperactivity Benefit shown in FXS Children Study Investigator to Participate in Conference Call and Webcast Today at 9:00 a.m. ET RADNOR, Pa., June 28, 2016 (GLOBE NEWSWIRE)...
27. Juni 2016 16:05 ET | Quelle: Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals to Host Conference Call on Tuesday, June 28

RADNOR, Pa., June 27, 2016 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy...
22. Juni 2016 07:30 ET | Quelle: Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals Doses First Subject in Phase 1 Clinical Trial for Ganaxolone IV

RADNOR, Pa., June 22, 2016 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy...
13. Juni 2016 07:30 ET | Quelle: Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals Announces Top-Line Results from Phase 3 Trial in Adult Focal Onset Seizures

RADNOR, Pa., June 13, 2016 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy...
03. Mai 2016 07:30 ET | Quelle: Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals to Participate in Bank of America Merrill Lynch Healthcare Conference

RADNOR, Pa., May 03, 2016 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and...
02. Mai 2016 07:30 ET | Quelle: Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2016 Financial Results

RADNOR, Pa., May 02, 2016 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and...
19. April 2016 07:30 ET | Quelle: Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals’ Ganaxolone IV Demonstrates Robust Efficacy in Benzodiazepine-Resistant Model of Status Epilepticus

Data Presented at the American Academy of Neurology Annual Meeting Phase 1 Clinical Program On-Track to Initiate in 1H 2016 RADNOR, Pa., April 19, 2016 (GLOBE NEWSWIRE) -- Marinus...
15. April 2016 07:30 ET | Quelle: Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone IV to Treat Status Epilepticus

RADNOR, Pa., April 15, 2016 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy...
12. April 2016 07:30 ET | Quelle: Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals to Present Ganaxolone IV Data at American Academy of Neurology Annual Meeting

RADNOR, Pa., April 12, 2016 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy...
07. März 2016 07:30 ET | Quelle: Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals Provides Business Update and 2015 Financial Results

RADNOR, Pa., March 07, 2016 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and...

Vorherige Seite